Amylyx Pharmaceuticals, Inc. AMLX
Institutional shares held
75.8 Million
212K
calls
40.6K
puts
Total value of holdings
$622M
$1.74M
calls
$333K
puts
Market Cap
$481M
58,533,200
Shares Out.
Institutional ownership
129.47%
# of Institutions
142
We take great care to ensure that the data presented and summarized in this overview for Amylyx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMLX
View all-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$72.2 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$64.9 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$48.8 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$37.2 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$36.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX3.26MShares$26.8 Million8.47% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.93MShares$24.1 Million0.82% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$21.9 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY2.16MShares$17.7 Million1.08% of portfolio
-
Almitas Capital LLC Santa Monica, CA2.12MShares$17.4 Million6.42% of portfolio
Latest Institutional Activity in AMLX
Top Purchases
Top Sells
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AMLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.72%
|
$120,000
$8.34 P/Share
|
|
Aug 12
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.02%
|
$120,000
$8.07 P/Share
|
|
May 22
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
1,000
-0.53%
|
-
|
|
Mar 31
2025
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,896
-3.61%
|
$32,688
$3.47 P/Share
|
|
Mar 31
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,192
-4.66%
|
$27,576
$3.48 P/Share
|
|
Mar 31
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,425
-6.01%
|
$37,275
$3.47 P/Share
|
|
Mar 31
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.47 P/Share
|
|
Mar 31
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.46 P/Share
|
|
Mar 20
2025
|
Bernhardt G Zeiher |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$30,000
$3.7 P/Share
|
|
Mar 06
2025
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+18.48%
|
-
|
|
Mar 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+24.86%
|
-
|
|
Mar 06
2025
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,851
+24.46%
|
-
|
|
Mar 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.15 P/Share
|
|
Mar 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,611
-1.19%
|
$4,833
$3.12 P/Share
|
|
Mar 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.17 P/Share
|
|
Feb 24
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,169
-3.0%
|
$12,507
$3.15 P/Share
|
|
Feb 05
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,310
+1.12%
|
$36,310
$1.57 P/Share
|
|
Feb 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,851
-0.37%
|
$35,553
$3.47 P/Share
|
Last 12 Months Summary
Buy / Acquisition
897K
Shares
From
11
Insiders
| Grant, award, or other acquisition | 561K shares |
|---|---|
| Open market or private purchase | 200K shares |
| Exercise of conversion of derivative security | 136K shares |
Sell / Disposition
254K
Shares
From
7
Insiders
| Open market or private sale | 226K shares |
|---|---|
| Bona fide gift | 28.9K shares |